Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Gets FDA Emergency Use Authorization for US Department of Defense Coronavirus Test

NEW YORK — The US Food and Drug Administration last week granted Emergency Use Authorization for an RT-PCR-based SARS-CoV-2 test developed by Cepheid for use by the US Department of Defense.

Cepheid's Xpert Xpress SARS-CoV-2 DoD test is designed to detect the N and E genes of the virus in upper respiratory specimens collected by healthcare providers. The test can be performed on Cepheid's automated GeneXpert Dx, GeneXpert Infinity, and GeneXpert Xpress systems and has been validated for use with pooled samples containing up to eight specimens.

Use of the test is limited to DoD-designated CLIA laboratories, according to the FDA.

Sunnyvale, California-based Cepheid previously received EUAs from the FDA for its Xpert Omni SARS-CoV-2 test and a multiplex SARS-CoV-2, influenza, and respiratory syncytial virus test.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.